Cellular and Molecular Biology of Complex Brain Disorders (R21 Clinical Trial Not Allowed)
ID: 349026Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Cellular and Molecular Biology of Complex Brain Disorders (R21 Clinical Trial Not Allowed)" aimed at advancing research on high-confidence risk factors associated with complex brain disorders such as schizophrenia and bipolar disorder. This grant encourages exploratory research focused on understanding the intracellular, transcellular, and circuit-level mechanisms of neural function, rather than modeling the disorders themselves. Eligible applicants, including various academic institutions and community organizations, can apply for up to $275,000 over a two-year period, with applications due by September 7, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-24-025.html.

    Point(s) of Contact
    Files
    Title
    Posted
    The Notice of Funding Opportunity (NOFO) issued by the Department of Health and Human Services, through the National Institutes of Health (NIH), focuses on research into the cellular and molecular biology of complex brain disorders. The R21 Exploratory/Developmental Research Grant encourages investigations into high-confidence risk factors associated with disorders such as schizophrenia and bipolar disorder, emphasizing intracellular and circuit-level contributions rather than disorder modeling. Eligible applicants, which include academic institutions and nonprofits, may apply for up to $275,000 over two years without the intent to conduct clinical trials. Applications must adhere to stringent guidelines regarding data management and sharing, requiring detailed resource sharing plans. Key dates for submission range from September 16, 2023, with various deadlines through 2026. The NOFO aims to foster innovative research approaches and the development of new tools that could lead to significant advances in understanding complex brain disorders, ultimately bridging the gap between biological mechanisms and potential therapeutic targets.
    Similar Opportunities
    Cellular and Molecular Biology of Complex Brain Disorders (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting proposals for the funding opportunity titled "Cellular and Molecular Biology of Complex Brain Disorders (R01 Clinical Trial Not Allowed)," aimed at advancing research on the biological mechanisms underlying complex brain disorders such as schizophrenia, bipolar disorder, and autism. This initiative encourages studies that explore high-confidence risk factors associated with these disorders, focusing on intracellular, transcellular, and circuit mechanisms, while emphasizing the importance of disseminating findings to enhance data resources and therapeutic target identification. Eligible applicants include a wide range of institutions, including historically black colleges, tribal colleges, and various nonprofit organizations, with applications due by September 7, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov, and detailed information can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-24-024.html.
    Cellular and Molecular Biology of Complex Brain Disorders (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for the R21 Clinical Trial Not Allowed grant, aimed at advancing research into the cellular and molecular biology of complex brain disorders. This funding opportunity encourages innovative research focused on high-confidence risk factors associated with conditions such as schizophrenia, major depression, and anxiety, emphasizing hypothesis-generating studies rather than disorder modeling. The grant supports projects with budgets up to $275,000 over a two-year period, with applications due starting January 16, 2025, and a closing date of September 7, 2026. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to review the full announcement available at https://grants.nih.gov/grants/guide/pa-files/PAR-25-037.html.
    Cellular and Molecular Biology of Complex Brain Disorders (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) titled "Cellular and Molecular Biology of Complex Brain Disorders (R01 Clinical Trial Not Allowed)," aimed at advancing research on high-confidence risk factors associated with complex brain disorders. This grant encourages studies that focus on the intracellular, transcellular, and circuit substrates of neural function, allowing for both hypothesis-generating and hypothesis-testing research designs, while discouraging attempts to model the disorders themselves. The initiative is crucial for enhancing understanding of the biological processes impacted by these disorders, ultimately facilitating therapeutic target identification and enriching data resources. Applications are due by September 7, 2026, with no budget cap, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Schizophrenia and related disorders during mid- to late-life (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Schizophrenia and Related Disorders During Mid- to Late-Life" (PAR-24-026), aimed at advancing research on the onset and progression of schizophrenia and related disorders in individuals aged 35 and older. This initiative seeks to promote high-risk exploratory and developmental projects that investigate neurobiological, psychosocial, and environmental factors contributing to these disorders, with a particular emphasis on addressing health disparities among minority and aging populations. The program offers a maximum funding amount of $275,000 over two years, with applications due by November 16, 2023, for the initial cycle. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders (R21 Clinical Trial Optional)." This grant aims to support innovative research utilizing invasive neural recording methods to explore the neural circuitry associated with mental health disorders, focusing on high-risk applications that address significant gaps in knowledge regarding complex moods and cognitive behaviors. The initiative seeks to bridge basic neuroscience with applied mental health interventions, encouraging diverse research teams to utilize advanced methodologies. The estimated funding amount is capped at $200,000, with applications due by January 7, 2028. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-291.html.
    Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Not Allowed) to support innovative and exploratory research projects in neuroscience. This grant program is designed for early-stage projects that align with the missions of the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute of Mental Health (NIMH), focusing on studies that assess the feasibility of novel investigations with the potential for significant breakthroughs in neuroscience. Eligible applicants include a wide range of organizations such as educational institutions, nonprofits, and foreign entities, with funding available up to $275,000 over two years. The application period opens on January 16, 2025, with anticipated awards by July 2025; interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Neuromodulation/Neurostimulation Device Development for Mental Health Applications (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Neuromodulation/Neurostimulation Device Development for Mental Health Applications," aimed at advancing the development of innovative brain stimulation devices for mental health disorders. This initiative seeks applications that either create novel brain stimulation technologies or significantly enhance existing FDA-approved devices through improvements in hardware and software, focusing on increased spatiotemporal precision and multi-focal, closed-loop approaches. The program is particularly important for addressing limitations in current mental health treatments and fostering technological innovation in this field. Interested applicants can apply for grants up to $275,000 for a two-year project period, with applications due by January 7, 2028. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-286.html.
    Schizophrenia and related disorders during mid- to late-life (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for exploratory research on schizophrenia and related disorders in individuals aged 35 and older, through the R21 grant mechanism. This initiative aims to enhance understanding of the onset, trajectory, and outcomes of these disorders in mid- to late-life, encouraging innovative studies that identify biological, behavioral, and environmental risk factors, as well as potential interventions. The funding, which can reach up to $275,000 over a maximum of two years, is crucial for addressing health disparities faced by older adults with these disorders and promoting novel solutions for their care. Applications are due between January 2025 and October 2026, and interested parties can contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    New Approaches for Measuring Brain Changes Across Longer Timespans (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "New Approaches for Measuring Brain Changes Across Longer Timespans (R21 Clinical Trial Optional)," aimed at fostering innovative research methodologies to study brain activity and structural changes over extended periods. This initiative encourages multidisciplinary collaborations to develop novel approaches or adapt existing techniques for measuring brain function across diverse age groups and clinical populations, with a focus on longitudinal data collection at multiple time points. The funding, capped at $275,000 over a two-year period, is intended for high-risk, high-reward exploratory research that enhances understanding of brain development and aging, with applications due by May 16, 2024, and subsequent deadlines. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-161.html.
    BRAIN Initiative: New Concepts and Early-Stage Research for Recording and Modulation in the Nervous System (R21) (Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a federal grant opportunity under the BRAIN Initiative for New Concepts and Early-Stage Research for Recording and Modulation in the Nervous System (R21). This initiative invites applications focused on developing innovative technologies to enhance the recording and manipulation of neural activity, particularly at unprecedented scales, while emphasizing the importance of diverse perspectives in the research process. The program aims to advance neuroscience research by addressing critical areas in understanding neural circuits and their functions, with an estimated total program funding of $200,000 and an award ceiling of $200,000 per project. Interested applicants must submit their proposals by June 15, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.